Articles
Ovarian cancer is a very difficult disease to diagnose and is the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States. Read More ›
This section provides a brief overview of new cancer drugs or new indications approved by the FDA between September 17 and September 26, 2019. Read More ›
Lost Earnings from Cancer-Related Deaths Cost the United States $94 Billion in 2015 Read More ›
By Wayne Kuznar
Chicago, IL—Tumor-specific antigens provide personalized targets for immunotherapy. Neoantigen vaccines are a new type of immunotherapy that can elicit immune response and achieve remission. Evidence is compelling to support neoantigens as the target of effective immune responses against cancer and to support an association between neoantigen load with improved clinical outcome, said Patrick Alexander Ott, MD, PhD, Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, at ASCO 2019.
Read More ›By Chase Doyle
San Diego, CA—Great progress has been made in the fight against cancer, but not all patients have benefited equally. Disparities exist among specific populations in terms of survival and cancer-related mortality, incidence and prevalence, as well as adverse health conditions, according to Karen M. Winkfield, MD, PhD, Director, Office of Cancer Health Equity, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC. Dr Winkfield discussed the topic at the 2019 ASCO Quality Care Symposium. Read More ›
People who are less engaged in their own medical care have more negative health consequences, including higher readmission rates, poor care coordination, and less confidence. Read More ›
Patients can be taught via neurofeedback to modify their brainwave activity and decrease the sensations of chemotherapy-induced peripheral neuropathy. Read More ›
San Francisco, CA—Adolescent and young adult (AYA) patients with cancer consistently indicate the need for better communication from their oncology providers on matters concerning sexual health. Despite misconceptions that the topic may embarrass them or fall on deaf ears, surveys show that AYAs actually want to talk to their providers about topics such as dating, safe sex practices during treatment, contraception, body image, sexuality, fertility, and psychosexual adjustment. Read More ›
San Francisco, CA—The human papillomavirus (HPV) has changed the field of head and neck cancer, and HPV now causes a growing majority (70%-90%) of oropharyngeal squamous-cell carcinomas. As its incidence is rising in the United States, so is patient curiosity about what sets this cancer apart from other malignancies. Read More ›
- Xospata Extends Overall Survival in Patients with FLT3 Mutation–Positive Relapsed or Refractory Acute Myeloid Leukemia
- Published Results from KEYNOTE-048 Trial Show Extended Survival with Keytruda in Advanced Head and Neck Cancers
- Discussing Costs of Genomic Testing with Patients